Provided by Tiger Trade Technology Pte. Ltd.

Amphastar Pharmaceuticals

19.01
-0.5200-2.66%
Post-market: 19.010.00000.00%19:59 EDT
Volume:346.02K
Turnover:6.67M
Market Cap:862.49M
PE:9.36
High:19.64
Open:19.37
Low:18.92
Close:19.53
52wk High:31.26
52wk Low:17.03
Shares:45.37M
Float Shares:34.22M
Volume Ratio:0.67
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):2.03
ROE:12.90%
ROA:6.37%
PB:1.09
PE(LYR):9.36

Loading ...

Amphastar Pharma Q4 Adj. EPS $0.73 Misses $0.92 Estimate, Sales $183.105M Miss $190.480M Estimate

Benzinga
·
Feb 27

BRIEF-Amphastar Pharmaceuticals Q4 EPS USD 0.51

Reuters
·
Feb 27

Amphastar Pharmaceuticals Q4 Adjusted EPS USD 0.73 VS. Ibes Estimate USD 0.92

THOMSON REUTERS
·
Feb 27

Amphastar Pharmaceuticals (AMPH) Gets a Buy from Jefferies

TIPRANKS
·
Feb 26

Amphastar Pharmaceuticals (AMPH) Receives a Hold from Bank of America Securities

TIPRANKS
·
Feb 25

FDA approves Amphastar’s Ipratropium Bromide HFA inhalation aerosol ANDA

Reuters
·
Feb 24

Amphastar Pharmaceuticals Inc. published an update to their financial calendar

Reuters
·
Feb 20

Is Amphastar (AMPH) Turning Margin Compression Into a Test of Its Operational Discipline?

Simply Wall St.
·
Feb 06

Amphastar Pharmaceuticals (AMPH) Gets a Hold from Bank of America Securities

TIPRANKS
·
Jan 20

A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin

Simply Wall St.
·
Jan 16

Amphastar Pharmaceuticals Showcases Pipeline Shift to Proprietary and Biosimilar Products in New Presentation

Reuters
·
Jan 13

Amphastar Pharmaceuticals: Made $2 Mln Upfront Payment to Hanxin Upon Signing

THOMSON REUTERS
·
Jan 12

Amphastar Pharmaceuticals: Additional Payments to Hanxin of up to $14 Mln in Development Milestone Payments, up to $75 Mln in Sales Milestone Payments

THOMSON REUTERS
·
Jan 12

Amphastar Pharmaceuticals: License Agreement With Nanjing Hanxin Pharmaceutical Technology for Fully Synthetic Corticotropin Compound

THOMSON REUTERS
·
Jan 12

Amphastar Pharmaceuticals Signs Exclusive License Agreement for Synthetic ACTH Compound

Reuters
·
Jan 12

Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum

Simply Wall St.
·
Jan 08

BofA Securities Adjusts Price Target on Amphastar Pharmaceuticals to $30 From $31, Maintains Neutral Rating

MT Newswires Live
·
Jan 08

Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says

MT Newswires Live
·
Jan 08

Amphastar Pharmaceuticals Senior EVP Rong Zhou Reports Disposal of Common Shares

Reuters
·
Dec 19, 2025

Director Floyd F. Petersen Reports Disposal of Amphastar Pharmaceuticals Inc. Common Shares

Reuters
·
Dec 16, 2025